Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886403 | 1.00 | POLB (0.55) | POLBAPPMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL15390317 | 0.95 | NPC1 (0.53) | POLBAPPMAPK1NPC1RAB9A | |
| SCHEMBL26702533 | 0.90 | APP (0.52) | APPMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL2158647 | 0.90 | NAAA (0.56) | POLBMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3196899 | 0.89 | RAB9A (0.55) | POLBAPPMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL13593371 | 0.87 | NAMPT (0.62) | POLBMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11214981 | 0.87 | APP (0.67) | APPMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1543504 | 0.86 | KLKB1 (0.55) | APPMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL11026787 | 0.85 | MAPK1 (0.58) | POLBAPPMAPK1ALDH1A1NAAA | |
| SCHEMBL5656378 | 0.85 | MAPK1 (0.58) | POLBAPPMAPK1ALDH1A1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116850132-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116831977-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116831978-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-03 | — | — | CN | claimed |
| US-20190022228-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2019-01-24 | — | — | US | claimed |
| EP-1781257-B1 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | EMISPHERE TECH INC (US) | 2018-12-19 | — | — | EP | claimed |
| EP-2579868-B1 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECH INC (US) | 2018-03-07 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| US-20160296599-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2016-10-13 | — | — | US | claimed |
| US-9402864-B2 | Oral iron deficiency therapy | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-08-02 | — | — | US | claimed |
| EP-1781257-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | Emisphere Technologies, Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| EP-1750729-A2 | SOLID DOSAGE FORM OF WETTED HEPARIN | Emisphere Technologies, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2007011958-A2 | INTRAORAL DOSAGE FORMS OF GLUCAGON | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2006124047-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-11-23 | — | — | WO | claimed |
| WO-2006017251-A2 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| WO-2005107773-A2 | SOLID DOSAGE FORM OF WETTED HEPARIN | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| EP-1175390-B1 | DISODIUM SALTS, MONOHYDRATES, AND ETHANOL SOLVATES | EMISPHERE TECH INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20050009748-A1 | Compositions for delivering peptide YY and PYY agonists | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-01-13 | — | — | US | claimed |
| US-20030216593-A1 | Method of preparing salicylamides | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2003-11-20 | — | — | US | claimed |
| WO-2001092206-A1 | METHOD OF PREPARING SALICYLAMIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009748-A1 | Compositions for delivering peptide YY and PYY agonists | NPY1R, NPY4R, NPY2R | POLB 4679/4885APP 255/4885MAPK1 3001/4885 |
| US-20190022228-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | CHMP4B, CD63, ADCYAP1R1 | POLB 4671/4885APP 1050/4885MAPK1 2885/4885 |
| US-20030216593-A1 | Method of preparing salicylamides | SCLY, ADSL, SIK3 | POLB 1212/4885APP 3888/4885MAPK1 2978/4885 |
| US-20160296599-A1 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AGONISTS | NPY1R, NPY4R, NPY2R | POLB 4676/4885APP 256/4885MAPK1 2971/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | POLB 2682/4885APP 3586/4885MAPK1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.